Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 37 peer-reviewed journal articles Updated
Pulmonology

How Can NSIP Patients Reduce Infection Risk Safely?

At a Glance

People receiving immune-suppressing treatment for NSIP can lower infection risk through recommended vaccines, hand and food safety, hepatitis B and TB screening, Pneumocystis pneumonia prevention when indicated, and prompt medical advice for fever, breathing changes, or low oxygen.

In this answer

6 sections

01

Daily Precautions: Hygiene and Social Contact

02

Vaccination and Household Protection

03

Medical Screening and Blood Test Monitoring

04

Preventing PJP Pneumonia

05

Action Plan for Symptoms and Oxygen Decline

06

Medication Rules During an Infection

Taking immunosuppressive medications like prednisone, mycophenolate, or rituximab for Non-Specific Interstitial Pneumonia (NSIP) lowers your body’s ability to fight off infections [1]. You can significantly reduce this risk by combining daily safety habits, staying up to date on vaccinations, participating in routine medical screening, and having a clear action plan for when you feel sick.

Daily Precautions: Hygiene and Social Contact

Your daily habits form the first line of defense against infections. Studies show that patients with weakened immune systems can reduce their exposure to pathogens by practicing good hand hygiene (washing with soap and water or using alcohol-based hand sanitizers) [2]. It is also recommended to wear a well-fitting mask in crowded indoor spaces, practice physical distancing, and avoid public or crowded places when respiratory viruses are circulating widely [2][3].

Avoid close contact with anyone who is actively sick [3]. When this is unavoidable (such as when a family member is ill), have them wear a mask, keep your distance, and improve indoor ventilation if possible. Because your immune system is less equipped to handle environmental pathogens, practice careful food and water safety (like cooking meats thoroughly) and avoid high-risk exposures like handling soil, bird droppings, or animal waste without protective gloves and thorough handwashing [2].

Vaccination and Household Protection

Vaccines train your immune system to recognize threats. Because your medications suppress immune function, your response to vaccines may be weaker while on treatment [4]. Whenever possible, it is best to get recommended vaccines before starting immunosuppressive therapy, without delaying urgent NSIP treatment unnecessarily [4].

  • Recommended Vaccines: Depending on your age, prior doses, and current local guidance, you will generally be advised to receive the seasonal flu vaccine, updated COVID-19 vaccines, pneumococcal vaccines (for pneumonia), recombinant shingles (zoster) vaccine, and age-appropriate RSV vaccination [5][6][7][8].
  • Live Vaccines: Because your immune system is suppressed, you must generally avoid “live” vaccines (which contain weakened forms of a virus) unless specifically directed by an infectious disease specialist or your pulmonologist [9].
  • Household Contacts: Ask your family members and anyone living with you to stay fully up to date on their vaccines; this lowers the chance of them bringing preventable infections into your home [10][8]. However, household members should ask their doctor if they need special instructions after receiving certain live vaccines, and they should stay away from you if they develop a rash or fever [10].

Medical Screening and Blood Test Monitoring

Before and during your treatment, your medical team will monitor you for hidden infections and check that your organs are handling the medications safely:

  • Hepatitis B and Tuberculosis (TB) Screening: Before starting targeted or intensive therapies, you should be screened for Hepatitis B with a full blood panel (HBsAg, total anti-HBc, and anti-HBs) and for latent TB, preferably using a blood test called an IGRA [11][12]. A positive result does not automatically cancel your NSIP treatment; it means your doctor may prescribe an antiviral or antibiotic to prevent the infection from reactivating, or they may monitor you closely [13][14].
  • Regular Blood Monitoring: Every medication requires a customized monitoring schedule. For example, azathioprine requires close monitoring of liver enzymes and complete blood counts (CBC) [15]. Cyclophosphamide requires regular CBC checks for low blood counts, as well as urine tests [16][17]. Tacrolimus can affect kidney function, requiring checks of your creatinine levels and blood drug levels [18][19]. Mycophenolate and rituximab also require specific monitoring for blood counts and organ function. Ensure you understand the specific blood tests required for your prescribed medications.

Preventing PJP Pneumonia

Pneumocystis jirovecii pneumonia (PJP) is a specific type of fungal lung infection that targets people with weakened immune systems. A common rule of thumb is that if you are taking a high dose of corticosteroids (such as 20 mg or more of prednisone daily for 4 weeks or longer), your risk for PJP increases significantly [20]. However, this threshold is not a guarantee; your individual risk also depends on whether you have a low lymphocyte count, are taking a combination of immunosuppressive drugs, your age, and your underlying lung disease [21][22][23].

To prevent PJP, your doctor may prescribe a preventative antibiotic, most commonly a sulfa drug called TMP-SMX [24]. This is typically taken daily or two to three times a week [24]. While taking TMP-SMX, your doctor will monitor your kidney function, potassium levels, and blood counts [25]. If you have a sulfa allergy or poor kidney function, alternatives like dapsone or atovaquone may be used [21].

Action Plan for Symptoms and Oxygen Decline

If you develop a new fever, a worsening cough, or increased shortness of breath, contact your medical team promptly. Do not assume it is just a cold. Acute respiratory deterioration in people with interstitial lung disease can be caused by a severe infection or an acute exacerbation (a sudden, dangerous worsening) of the NSIP itself, both of which require urgent medical assessment rather than waiting it out at home [26][27][28]. Be aware that a fever (commonly defined as 100.4°F or 38.0°C) should be reported to your doctor immediately, but the absence of fever does not rule out infection in immunosuppressed patients [29].

When to Seek Emergency Care:
Do not wait for a callback if you experience any of these “red flag” symptoms:

  • Severe or rapidly worsening breathlessness
  • Blue lips or face
  • New confusion or fainting
  • Chest pain or inability to speak in full sentences
  • Persistently low oxygen readings according to your personalized plan

Using a Pulse Oximeter:
Pulse oximeter readings can be inaccurate. Ensure your finger is warm, hold your hand still, and wait for a steady signal [30][31]. Most importantly, if you feel severe symptoms, seek help even if the oxygen reading appears normal [31].

Medication Rules During an Infection

If you feel sick or suspect an infection, do not change or stop any medication on your own; contact the prescribing team urgently.

  • The Danger of Stopping Prednisone Abruptly: Taking systemic glucocorticoids (steroids like prednisone) over time suppresses your body’s natural ability to produce its own stress hormones (cortisol) [32]. Stopping them suddenly can cause an adrenal crisis, a life-threatening condition that causes dangerously low blood pressure, severe fatigue, and altered mental status [33][34]. Never stop long-term prednisone abruptly without a clinician-directed taper or sick-day plan [32][35].
  • Holding Other Immunosuppressants: While prednisone should not be stopped suddenly, your doctor may advise you to temporarily hold or delay other immunosuppressants (like mycophenolate, azathioprine, or rituximab) to allow your immune system to better fight the infection [36][37]. Always follow your doctor’s specific instructions for each medication.

Common questions in this guide

Which vaccines may I need while taking immunosuppressive treatment for NSIP?
Depending on your age, prior doses, and current guidance, clinicians commonly consider seasonal flu, updated COVID-19, pneumococcal, recombinant shingles, and age-appropriate RSV vaccines. Vaccine responses may be weaker during immune-suppressing treatment, so ask whether any can be given before treatment starts without delaying necessary NSIP care. Live vaccines are generally avoided unless a specialist specifically recommends one.
How do I know whether I need prevention for Pneumocystis pneumonia during NSIP treatment?
A daily prednisone dose of about 20 mg or more for at least 4 weeks raises the risk of Pneumocystis jirovecii pneumonia, also called PJP, but lymphocyte count, combination therapy, age, and lung disease also matter. Your clinician may prescribe TMP-SMX daily or two to three times weekly, or dapsone or atovaquone if TMP-SMX is unsuitable. Monitoring may include blood counts, kidney function, and potassium.
What infection screening is needed before stronger NSIP immunosuppression?
Before targeted or intensive therapy, clinicians commonly test for hepatitis B using HBsAg, total anti-HBc, and anti-HBs, and screen for latent tuberculosis with an IGRA blood test. A positive result does not automatically mean NSIP treatment must stop; the team may use preventive medicine or closer monitoring.
When should I call for help if I might have an infection during NSIP treatment?
Contact your medical team promptly for a new fever of 100.4°F (38°C), worsening cough, increased breathlessness, or a drop in oxygen from your personalized baseline; no fever does not rule out infection. Seek emergency care for severe or rapidly worsening breathing trouble, blue lips or face, confusion or fainting, chest pain, inability to speak in full sentences, or persistently low oxygen according to your plan.
Should I stop prednisone or my other NSIP medicines if I become sick?
Do not change or stop any medicine on your own; contact the prescribing team urgently for instructions. Stopping long-term prednisone suddenly can cause a life-threatening adrenal crisis, while a clinician may sometimes tell you to hold or delay medicines such as mycophenolate, azathioprine, or rituximab during an infection.
How can my household reduce my infection exposure while I take NSIP immunosuppressants?
Household members should stay up to date on recommended vaccines and ask their own clinician about any live vaccine. If someone develops an illness, masking, distance, and better ventilation can reduce exposure; household members should avoid close contact and stay away after certain live vaccines if they develop a rash or fever.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Related questions

What is the Prognosis and Life Expectancy for NSIP? Can NSIP Go Into Remission or Relapse? What to Know What Do Ground-Glass, Reticulation & Traction Mean in NSIP? NSIP vs IPF: How Are These Lung Diseases Different? What Is the Difference Between Cellular and Fibrotic NSIP?
Show more
How Do Doctors Define Progressive Fibrosis in Fibrotic NSIP? Can Lung Scarring From Fibrotic NSIP Be Reversed? Explained Can Autoimmune Disease Cause NSIP Before Other Symptoms? Can Medication Side Effects Cause NSIP? What to Know How Is NSIP Differentiated From Fibrotic HP on HRCT? Can Autoimmune NSIP Occur With Negative Blood Tests? What Does “Nonspecific” Mean in an NSIP Diagnosis? How Common Is NSIP, and Why Is Diagnosis Difficult? Is NSIP Contagious or Cancer? What Patients Should Know Do I Need a Lung Biopsy to Diagnose NSIP Lung Disease? Which Home and Work Exposures Should Be Checked in NSIP? Why Does Multidisciplinary Review Matter for NSIP Diagnosis? Can Pneumocystis Pneumonia (PJP) Mimic an NSIP Flare? What Is an Acute Exacerbation of NSIP? Emergency Signs

Get notified when new evidence is published on Non-specific interstitial pneumonia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific vaccines do I need, and can we schedule them before I start or increase my immunosuppressive medications?
  2. 2.Based on my prednisone dose, lymphocyte count, and other medications, do I need a preventative antibiotic for PJP?
  3. 3.At what pulse oximeter reading or specific temperature should I contact the office or go to the emergency room?
  4. 4.How frequently will I need blood tests to monitor my liver, kidneys, and complete blood count (CBC) on my specific medications?
  5. 5.If I get sick after hours or on a weekend, who should I contact for instructions on whether to hold medications like mycophenolate or rituximab?

References

References (37)
  1. 1

    Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease.

    Lee JS, Fischer A

    Expert review of clinical immunology 2016; (12(5)):509-20 doi:10.1586/1744666X.2016.1139454.

    PMID: 26752397
  2. 2

    Determinants of COVID-19 preventive behaviours among adults with chronic diseases in the USA: an analysis of the nationally representative COVID-19 impact survey.

    Islam JY, Vidot DC, Camacho-Rivera M

    BMJ open 2021; (11(2)):e044600 doi:10.1136/bmjopen-2020-044600.

    PMID: 33563624
  3. 3

    Preventive Behaviors and Mental Health-Related Symptoms Among Immunocompromised Adults During the COVID-19 Pandemic: An Analysis of the COVID Impact Survey.

    Islam JY, Vidot DC, Havanur A, Camacho-Rivera M

    AIDS research and human retroviruses 2021; (37(4)):304-313 doi:10.1089/AID.2020.0302.

    PMID: 33626959
  4. 4

    Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy.

    Garcia Garrido HM, Vollaard A, D'Haens GR, et al.

    Vaccines 2022; (10(5)) doi:10.3390/vaccines10050795.

    PMID: 35632551
  5. 5

    Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024.

    Link-Gelles R, Rowley EAK, DeSilva MB, et al.

    MMWR. Morbidity and mortality weekly report 2024; (73(12)):271-276 doi:10.15585/mmwr.mm7312a5.

    PMID: 38547037
  6. 6

    Invasive Pneumococcal Disease and Potential Impact of Pneumococcal Conjugate Vaccines Among Adults, Including Persons Experiencing Homelessness-Alaska, 2011-2020.

    Steinberg J, Bressler SS, Orell L, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024; (78(1)):172-178 doi:10.1093/cid/ciad597.

    PMID: 37787072
  7. 7

    Knowledge, Attitudes, and Practices Regarding Herpes Zoster Vaccination Among Specialists.

    Singer D, Sweeney C, Stempniewicz N, et al.

    Population health management 2024; (27(4)):231-240 doi:10.1089/pop.2023.0284.

    PMID: 38838030
  8. 8

    IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal RSV Infections in Immunocompromised Patients.

    Tan CS, Anjan S, Ariza-Heredia EJ, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026; (82(Suppl 3)):i123-i128 doi:10.1093/cid/ciag117.

    PMID: 41766598
  9. 9

    Measles Vaccine Boosters in Immunocompromised Adults to Reduce Morbidity and Mortality From Acute Measles Infection: A Scoping Review.

    Price I, Smith PK, Tan A, et al.

    Cureus 2026; (18(8)):e115440 doi:10.7759/cureus.115440.

    PMID: 42812866
  10. 10

    Vaccination of Adults With Cancer: ASCO Guideline.

    Kamboj M, Bohlke K, Baptiste DM, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(14)):1699-1721 doi:10.1200/JCO.24.00032.

    PMID: 38498792
  11. 11

    Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention.

    Abara WE, Qaseem A, Schillie S, et al.

    Annals of internal medicine 2017; (167(11)):794-804 doi:10.7326/M17-1106.

    PMID: 29159414
  12. 12

    To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.

    Ahn CS, Dothard EH, Garner ML, et al.

    Journal of the American Academy of Dermatology 2015; (73(3)):420-8.e1.

    PMID: 26184440
  13. 13

    Prevention of Hepatitis B Reactivation in Patients Receiving Immunosuppressive Therapy: a Case Series and Appraisal of Society Guidelines.

    Etienne S, Vosbeck J, Bernsmeier C, Osthoff M

    Journal of general internal medicine 2023; (38(2)):490-501 doi:10.1007/s11606-022-07806-9.

    PMID: 36138278
  14. 14

    2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases.

    Fragoulis GE, Nikiphorou E, Dey M, et al.

    Annals of the rheumatic diseases 2023; (82(6)):742-753 doi:10.1136/ard-2022-223335.

    PMID: 36328476
  15. 15

    Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease.

    Boerner EB, Cuyas M, Theegarten D, et al.

    Respiration; international review of thoracic diseases 2020; (99(8)):628-636 doi:10.1159/000508540.

    PMID: 32663826
  16. 16

    Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis.

    Wang P, Zhang L, Guo Q, et al.

    Open medicine (Warsaw, Poland) 2023; (18(1)):20230838 doi:10.1515/med-2023-0838.

    PMID: 38025531
  17. 17

    Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

    Tashkin DP, Roth MD, Clements PJ, et al.

    The Lancet. Respiratory medicine 2016; (4(9)):708-719 doi:10.1016/S2213-2600(16)30152-7.

    PMID: 27469583
  18. 18

    Successful Treatment of a Patient with Drug-Refractory Rheumatoid Arthritis-Associated Interstitial Lung Disease with Upadacitinib: A Case Report.

    Nishii Y, Okamoto M, Zaizen Y, et al.

    Medicina (Kaunas, Lithuania) 2023; (59(11)) doi:10.3390/medicina59111960.

    PMID: 38004009
  19. 19

    Initial Dosage Optimization of Tacrolimus in Connective Tissue Disease-Associated Interstitial Lung Disease Patients: An Exploratory Study.

    Zhang GY, Jin YW, Wang J, et al.

    Drug design, development and therapy 2026; (20()):620915 doi:10.2147/DDDT.S620915.

    PMID: 42824096
  20. 20

    Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.

    Mecoli CA, Saylor D, Gelber AC, Christopher-Stine L

    Clinical and experimental rheumatology 2017; (35(4)):671-673.

    PMID: 28134084
  21. 21

    Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases.

    Ghembaza A, Vautier M, Cacoub P, et al.

    Chest 2020; (158(6)):2323-2332 doi:10.1016/j.chest.2020.05.558.

    PMID: 32502592
  22. 22

    Pneumocystis jirovecii pneumonia in patients treated for systemic autoimmune disorders: a retrospective analysis of patient characteristics and outcome.

    Verhaert M, Blockmans D, De Langhe E, Henckaerts L

    Scandinavian journal of rheumatology 2020; (49(5)):345-352 doi:10.1080/03009742.2020.1762921.

    PMID: 32662308
  23. 23

    Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study.

    Hsu HC, Chang YS, Hou TY, et al.

    Clinical rheumatology 2021; (40(9)):3755-3763 doi:10.1007/s10067-021-05660-4.

    PMID: 33646447
  24. 24

    ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.

    Maertens J, Cesaro S, Maschmeyer G, et al.

    The Journal of antimicrobial chemotherapy 2016; (71(9)):2397-404 doi:10.1093/jac/dkw157.

    PMID: 27550992
  25. 25

    Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.

    Kitazawa T, Seo K, Yoshino Y, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2019; (25(5)):351-354 doi:10.1016/j.jiac.2019.01.005.

    PMID: 30711257
  26. 26

    Acute Exacerbation in Interstitial Lung Disease.

    Leuschner G, Behr J

    Frontiers in medicine 2017; (4()):176 doi:10.3389/fmed.2017.00176.

    PMID: 29109947
  27. 27

    Acute Exacerbation of Interstitial Lung Disease After SARS-CoV-2 Vaccination: A Case Series.

    Ishioka Y, Makiguchi T, Itoga M, et al.

    Chest 2022; (162(6)):e311-e316 doi:10.1016/j.chest.2022.08.2213.

    PMID: 36494131
  28. 28

    Prognostic value of serum oncomarkers for patients hospitalized with acute exacerbation of interstitial lung disease.

    Ba C, Jiang C, Wang H, et al.

    Therapeutic advances in respiratory disease 2024; (18()):17534666241250332 doi:10.1177/17534666241250332.

    PMID: 38757948
  29. 29

    General Approach to Immunocompromised Patients with Pneumonia: Insights from the Latest Consensus Documents.

    Ramirez JA

    Seminars in respiratory and critical care medicine 2026; (47(2)):184-189 doi:10.1055/a-2709-6182.

    PMID: 40997866
  30. 30

    Comparison of forehead and finger oximetry sensors during the six minute walk test.

    Robertson L, Lowry R, Sylvester K, et al.

    Chronic respiratory disease 2022; (19()):14799731211070844 doi:10.1177/14799731211070844.

    PMID: 35045761
  31. 31

    Spurious Fingertip Oxygen Desaturation During the 6-Minute Walk Test in a Patient With NSIP and Raynaud Phenomenon: The Value of Forehead Pulse Oximetry and Transcutaneous Oxygen Tension.

    Nakamura Y, Takamori M, Sunaga H, et al.

    Respirology case reports 2026; (14(8)):e70737 doi:10.1002/rcr2.70737.

    PMID: 42643888
  32. 32

    European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency.

    Beuschlein F, Else T, Bancos I, et al.

    The Journal of clinical endocrinology and metabolism 2024; (109(7)):1657-1683 doi:10.1210/clinem/dgae250.

    PMID: 38724043
  33. 33

    Adrenal Insufficiency in Adults: A Review.

    Vaidya A, Findling J, Bancos I

    JAMA 2025; (334(8)):714-725 doi:10.1001/jama.2025.5485.

    PMID: 40522647
  34. 34

    Adrenal crisis: prevention and management in adult patients.

    Dineen R, Thompson CJ, Sherlock M

    Therapeutic advances in endocrinology and metabolism 2019; (10()):2042018819848218 doi:10.1177/2042018819848218.

    PMID: 31223468
  35. 35

    Is there a safe and effective way to wean patients off long-term glucocorticoids?

    Baker EH

    British journal of clinical pharmacology 2020; doi:10.1111/bcp.14679.

    PMID: 33289121
  36. 36

    Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.

    Mankikian J, Caille A, Reynaud-Gaubert M, et al.

    The European respiratory journal 2023; (61(6)) doi:10.1183/13993003.02071-2022.

    PMID: 37230499
  37. 37

    Rituximab in connective tissue disease-associated interstitial lung disease.

    Duarte AC, Cordeiro A, Fernandes BM, et al.

    Clinical rheumatology 2019; (38(7)):2001-2009 doi:10.1007/s10067-019-04557-7.

    PMID: 31016581

This page is for informational purposes only and does not constitute medical advice. It explains infection prevention during NSIP immunosuppressive treatment, but your pulmonologist and prescribing team must tailor vaccines, monitoring, PJP prevention, and sick-day medication instructions to you.